Neutrophils as effector cells for antibody-based immunotherapy of cancer

Seminars in Cancer Biology

Volumn 23, Issue 3, 2013, Pages 190-199

  Van Egmond, Marjolein ^a   Bakema, Jantine E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fc receptor; Immunoglobulin A; Monoclonal antibody; Neutrophil; Tumour cell

Indexed keywords

ALEMTUZUMAB; BCG VACCINE; BETA GLUCAN; BISPECIFIC ANTIBODY; CD20 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC ALPHA RECEPTOR I; FC RECEPTOR; GAMMA INTERFERON; GANGLIOSIDE GD2 ABTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MDX 210; MDX 447; MDX H210; MONOCLONAL ANTIBODY; PANITUMUMAB; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CYTOTOXICITY; DRUG POTENTIATION; DRUG WITHDRAWAL; EFFECTOR CELL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOREGULATION; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEUTROPHILS;

EID: 84876966731     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.12.002     Document Type: Review

References (124)

1. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nature Reviews Cancer 2012, 12:278-287.
2. Amoroso A., Hafsi S., Militello L., Russo A.E., Soua Z., Mazzarino M.C., et al. Understanding rituximab function and resistance: implications for tailored therapy. Frontiers in Bioscience 2011, 16:770-782.
3. Weiner L.M., Murray J.C., Shuptrine C.W. Antibody-based immunotherapy of cancer. Cell 2012, 148:1081-1084.
4. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery 2010, 9:767-774.
5. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. New England Journal of Medicine 2007, 357:39-51.
6. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Research 2007, 67:2643-2648.
7. Hogarth P.M., Pietersz G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nature Reviews Drug Discovery 2012, 11:311-331.
8. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038-1043.
9. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology 2007, 44:3823-3837.
10. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends in Immunology 2004, 25:158-164.
11. Racila E., Link B.K., Weng W.K., Witzig T.E., Ansell S., Maurer M.J., et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical Cancer Research 2008, 14:6697-6703.
12. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Current Opinion in Immunology 2007, 19:239-245.
13. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:652-656.
14. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 2000, 6:443-446.
15. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Research 2010, 70:3209-3217.
16. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
17. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology 2003, 21:3940-3947.
18. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. Journal of Clinical Oncology 2008, 26:1789-1796.
19. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. Journal of Clinical Oncology 2009, 27:1122-1129.
20. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
21. Minard-Colin V., Xiu Y., Poe J.C., Horikawa M., Magro C.M., Hamaguchi Y., et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008, 112:1205-1213.
22. van der Bij G.J., Bogels M., Otten M.A., Oosterling S.J., Kuppen P.J., Meijer S., et al. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. Journal of Hepatology 2010, 53:677-685.
23. van Egmond M. Neutrophils in antibody-based immunotherapy of cancer. Expert Opinion on Biological Therapy 2008, 8:83-94.
24. Otten M.A., van der Bij G.J., Verbeek S.J., Nimmerjahn F., Ravetch J.V., Beelen R.H., et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. Journal of Immunology 2008, 181:6829-6836.
25. Amulic B., Cazalet C., Hayes G.L., Metzler K.D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annual Review of Immunology 2012, 30:459-489.
26. Di Carlo E., Forni G., Lollini P., Colombo M.P., Modesti A., Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
27. Midorikawa Y., Yamashita T., Sendo F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Research 1990, 50:6243-6247.
28. Suttmann H., Riemensberger J., Bentien G., Schmaltz D., Stöckle M., Jocham D., et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Research 2006, 66:8250-8257.
29. Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1)+(2). New England Journal of Medicine 1992, 327. 28-35; 99-106.
30. Colombo M.P., Ferrari G., Stoppacciaro A., Parenza M., Rodolfo M., Mavilio F., et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. Journal of Experimental Medicine 1991, 173(April (4)):889-897.
31. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009, 16:183-194.
32. Ravetch J.V., Bolland S. IgG Fc receptors. Annual Review of Immunology 2001, 19:275-290.
33. Siders W.M., Shields J., Garron C., Hu Y., Boutin P., Shankara S., et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia and Lymphoma 2010, 51:1293-1304.
34. Lundin J., Kimby E., Björkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768-773.
35. Ambrose L.R., Morel A.S., Warrens A.N. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 2009, 114:3052-3055.
36. Hernandez-Ilizaliturri F.J., Jupudy V., Ostberg J., Oflazoglu E., Huberman A., Repasky E., et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research 2003, 9:5866-5873.
37. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., van Oers M.H. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003, 17:1658-1664.
38. Niitsu N., Hayama M., Okamoto M., Khori M., Higashihara M., Tamaru J., et al. Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clinical Cancer Research 2004, 10:4077-4082.
39. Cartron G., Zhao-Yang L., Baudard M., Kanouni T., Rouillé V., Quittet P., et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. Journal of Clinical Oncology 2008, 26:2725-2731.
40. Valerius T., Wurflein D., Stockmeyer B., Repp R., Kalden J.R., Gramatzki M. Activated neutrophils as effector cells for bispecific antibodies. Cancer Immunology, Immunotherapy 1997, 45:142-145.
41. Cartron G., Ohresser M., Salles G., Solal-Céligny P., Colombat P., Watier H. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. Annals of Oncology 2008, 19:1485-1487.
42. Masuda K., Kubota T., Kaneko E., Iida S., Wakitani M., Kobayashi-Natsume Y., et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Molecular Immunology 2007, 44:3122-3131.
43. Nakagawa T., Natsume A., Satoh M., Niwa R. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leukemia Research 2010, 34:666-671.
44. Ottonello L., Epstein A.L., Mancini M., Dapino P., Dallegri F. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. Journal of Leukocyte Biology 2004, 75:99-105.
45. Cheung N.K., Sowers R., Vickers A.J., Cheung I.Y., Kushner B.H., Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. Journal of Clinical Oncology 2006, 24:2885-2890.
46. Kushner B.H., Cheung N.K. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumour cells by polymorphonuclear leukocytes. Cancer Research 1991, 51:4865-4870.
47. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., Rossen K., van Berkel P.H., Derer S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. Journal of Immunology 2010, 184:512-520.
48. Su K., Yang H., Li X., Li X., Gibson A.W., Cafardi J.M., et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. Journal of Immunology 2007, 178:3272-3280.
49. Hong F., Hansen R.D., Yan J., Allendorf D.J., Baran J.T., Ostroff G.R., et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Research 2003, 63:9023-9031.
50. Liu J., Gunn L., Hansen R., Yan J. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Experimental and Molecular Pathology 2009, 86(June (3)):208-214.
51. Zhong W., Hansen R., Li B., Cai Y., Salvador C., Moore G.D., et al. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. Journal of Immunotherapy 2009, 32(September (7)):703-712.
52. van Spriel A.B., van Ojik H.H., Bakker A., Jansen M.J., van de Winkel J.G. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003, 101:253-258.
53. van Spriel A.B., Leusen J.H., van Egmond M., Dijkman H.B., Assmann K.J., Mayadas T.N., et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001, 97:2478-2486.
54. Li B., Allendorf D.J., Hansen R., Marroquin J., Cramer D.E., Harris C.L., et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Research 2007, 67:7421-7430.
55. Valerius T., Repp R., de Wit T.P., Berthold S., Platzer E., Kalden J.R., et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993, 82:931-939.
56. van Spriel A.B., van Ojik H.H., van De Winkel J.G. Immunotherapeutic perspective for bispecific antibodies. Immunology Today 2000, 21:391-397.
57. Stockmeyer B., Valerius T., Repp R., Heijnen I.A., Bühring H.J., Deo Y.M., et al. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Research 1997, 57:696-701.
58. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunology, Immunotherapy 1997, 45:210-215.
59. Heijnen I.A., Rijks L.J., Schiel A., Stockmeyer B., van Ojik H.H., Dechant M., et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. Journal of Immunology 1997, 159:5629-5639.
60. Honeychurch J., Tutt A.L., Valerius T., Heijnen I.A., Van De Winkel J.G., Glennie M.J. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000, 96:3544-3552.
61. van Ojik H.H., Bevaart L., Dahle C.E., Bakker A., Jansen M.J., van Vugt M.J., et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Research 2003, 63:5595-5600.
62. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. Journal of Clinical Oncology 1995, 13:2281-2292.
63. Fury M.G., Lipton A., Smith K.M., Winston C.B., Pfister D.G. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunology, Immunotherapy 2008, 57:155-163.
64. Repp R., van Ojik H.H., Valerius T., Groenewegen G., Wieland G., Oetzel C., et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI×anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. British Journal of Cancer 2003, 89:2234-2243.
65. Pullarkat V., Deo Y., Link J., Spears L., Marty V., Curnow R., et al. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunology, Immunotherapy 1999, 48:9-21.
66. James N.D., Atherton P.J., Jones J., Howie A.J., Tchekmedyian S., Curnow R.T. A phase II study of the bispecific antibody MDX-H210 (anti-HER2×CD64) with GM-CSF in HER2+ advanced prostate cancer. British Journal of Cancer 2001, 85:152-156.
67. Lewis L.D., Beelen A.P., Cole B.F., Wallace P.K., Fisher J.L., Waugh M.G., et al. The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 2002, 49:375-384.
68. Otten M.A., Rudolph E., Dechant M., Tuk C.W., Reijmers R.M., Beelen R.H., et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. Journal of Immunology 2005, 174:5472-5480.
69. Bevaart L., Jansen M.J., van Vugt M.J., Verbeek J.S., van de Winkel J.G., Leusen J.H. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research 2006, 66:1261-1264.
70. Valerius T., Stockmeyer B., van Spriel A.B., Graziano R.F., van den Herik-Oudijk I.E., Repp R., et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997, 90:4485-4492.
71. Deo Y.M., Sundarapandiyan K., Keler T., Wallace P.K., Graziano R.F. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumour antigens efficiently promote cell-mediated cytotoxicity of tumour targets in whole blood. Journal of Immunology 1998, 160:1677-1686.
72. Monteiro R.C., Kubagawa H., Cooper M.D. Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. Journal of Experimental Medicine 1990, 171:597-613.
73. van Egmond M., van Garderen E., van Spriel A.B., Damen C.A., van Amersfoort E.S., van Zandbergen G., et al. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nature Medicine 2000, 6:680-685.
74. Bakema J.E., van Egmond M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunology 2011, 4:612-624.
75. Qian K., Xie F., Gibson A.W., Edberg J.C., Kimberly R.P., Wu J. Functional expression of IgA receptor FcalphaRI on human platelets. Journal of Leukocyte Biology 2008, 84:1492-1500.
76. Pasquier B., Launay P., Kanamaru Y., Moura I.C., Pfirsch S., Ruffié C., et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005, 22:31-42.
77. Monteiro R.C., Van De Winkel J.G. IgA Fc receptors. Annual Review of Immunology 2003, 21:177-204.
78. Bakema J.E., van Egmond M., Immunoglobulin A. A next generation of therapeutic antibodies. Monoclonal Antibody 2011, 3:352-361.
79. Huls G., Heijnen I.A., Cuomo E., van der Linden J., Boel E., van de Winkel J.G., et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Research 1999, 59:5778-5784.
80. Stockmeyer B., Dechant M., van Egmond M., Tutt A.L., Sundarapandiyan K., Graziano R.F., et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. Journal of Immunology 2000, 165:5954-5961.
81. Dechant M., Valerius T. IgA antibodies for cancer therapy. Critical Reviews in Oncology/Hematology 2001, 39:69-77.
82. van Egmond M., van Spriel A.B., Vermeulen H., Huls G., van Garderen E., van de Winkel J.G. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). Cancer Research 2001, 61:4055-4060.
83. Dechant M., Beyer T., Schneider-Merck T., Weisner W., Peipp M., van de Winkel J.G., et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. Journal of Immunology 2007, 179:2936-2943.
84. Zhao J., Kuroki M., Shibaguchi H., Wang L., Huo Q., Takami N., et al. Recombinant human monoclonal IgA antibody against CEA to recruit neutrophils to CEA-expressing cells. Oncology Research 2008, 17:217-222.
85. Guettinger Y., Barbin K., Peipp M., Bruenke J., Dechant M., Horner H., et al. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. Journal of Immunology 2010, 184:1210-1217.
86. Lohse S., Derer S., Beyer T., Klausz K., Peipp M., Leusen J.H., et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. Journal of Immunology 2011, 186:3770-3778.
87. Pfefferkorn L.C., Yeaman G.R. Association of IgA-Fc receptors (Fc alpha R) with Fc epsilon RI gamma 2 subunits in U937 cells. Aggregation induces the tyrosine phosphorylation of gamma 2. Journal of Immunology 1994, 153:3228-3236.
88. van Egmond M., van Vuuren A.J., Morton H.C., van Spriel A.B., Shen L., Hofhuis F.M., et al. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999, 93:4387-4394.
89. Van den Herik-Oudijk I.E., Ter Bekke M.W., Tempelman M.J., Capel P.J., Van de Winkel J.G. Functional differences between two Fc receptor ITAM signaling motifs. Blood 1995, 86:3302-3307.
90. van Vugt M.J., Heijnen A.F., Capel P.J., Park S.Y., Ra C., Saito T., et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood 1996, 87:3593-3599.
91. Morton H.C., van den Herik-Oudijk I.E., Vossebeld P., Snijders A., Verhoeven A.J., Capel P.J., et al. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. Journal of Biological Chemistry 1995, 270:29781-29787.
92. Bakema J.E., de Haij S., den Hartog-Jager C.F., Bakker J., Vidarsson G., van Egmond M., et al. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. Journal of Immunology 2006, 176:3603-3610.
93. Wines B.D., Trist H.M., Monteiro R.C., Van Kooten C., Hogarth P.M. Fc receptor gamma chain residues at the interface of the cytoplasmic and transmembrane domains affect association with FcalphaRI, surface expression, and function. Journal of Biological Chemistry 2004, 279:26339-26345.
94. Otten M.A., Leusen J.H., Rudolph E., van der Linden J.A., Beelen R.H., van de Winkel J.G., et al. FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI. Journal of Immunology 2007, 179:2918-2924.
95. van der Steen L., Tuk C.W., Bakema J.E., Kooij G., Reijerkerk A., Vidarsson G., et al. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 2009, 137:2018-2029.
96. Otten M.A., Bakema J.E., Tuk C.W., Glennie M.J., Tutt A.L., Beelen R.H., et al. Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. European Journal of Immunology 2012, 42:1815-1821.
97. Launay P., Grossetête B., Arcos-Fajardo M., Gaudin E., Torres S.P., Beaudoin L., et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. Journal of Experimental Medicine 2000, 191:1999-2009.
98. Beyer T., Lohse S., Berger S., Peipp M., Valerius T., Dechant M. Serum-free production and purification of chimeric IgA antibodies. Journal of Immunological Methods 2009, 346:26-37.
99. Duchez S., Amin R., Cogné N., Delpy L., Sirac C., Pascal V., et al. Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3064-3069.
100. Pascal V., Laffleur B., Debin A., Cuvillier A., van Egmond M., Drocourt D., et al. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica 2012, 97:1686-1694.
101. Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. Journal of Clinical Investigation 1991, 88:93-100.
102. Clark R.A., Klebanoff S.J. Neutrophil-mediated tumour cell cytotoxicity: role of the peroxidase system. Journal of Experimental Medicine 1975, 141:1442-1447.
103. Horner H., Frank C., Dechant C., Repp R., Glennie M., Herrmann M., et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. Journal of Immunology 2007, 179:337-345.
104. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
105. Saffarzadeh M., Juenemann C., Queisser M.A., Lochnit G., Barreto G., Galuska S.P., et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE 2012, 7:e32366.
106. Hubert P., Heitzmann A., Viel S., Nicolas A., Sastre-Garau X., Oppezzo P., et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Research 2011, 71:5134-5143.
107. Wagner C., Iking-Konert C., Denefleh B., Stegmaier S., Hug F., Hansch G.M. Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils. Blood 2004, 103:1099-1104.
108. Hochegger K., Eller P., Rosenkranz A.R. Granzyme A: an additional weapon of human polymorphonuclear neutrophils (PMNs) in innate immunity?. Blood 2004, 103:1176.
109. Grossman W.J., Ley T.J. Granzymes A and B are not expressed in human neutrophils. Blood 2004, 104:906-907.
110. Metkar S.S., Froelich C.J. Human neutrophils lack granzyme A, granzyme B, and perforin. Blood 2004, 104:905-906.
111. Stockmeyer B., Beyer T., Neuhuber W., Repp R., Kalden J.R., Valerius T., et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. Journal of Immunology 2003, 171:5124-5129.
112. Bakema J.E., Ganzevles S.H., Fluitsma D.M., Schilham M.W., Beelen R.H., Valerius T., et al. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. Journal of Immunology 2011, 187:726-732.
113. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
114. Shen S., Kepp O., Kroemer G. The end of autophagic cell death?. Autophagy 2012, 8(January):1-3.
115. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews Immunology 2011, 11:519-531.
116. Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010, 115:335-343.
117. Oehler L., Majdic O., Pickl W.F., Stöckl J., Riedl E., Drach J., et al. Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. Journal of Experimental Medicine 1998, 187:1019-1028.
118. van Gisbergen K.P., Geijtenbeek T.B., van Kooyk Y. Close encounters of neutrophils and DCs. Trends in Immunology 2005, 26:626-631.
119. van Gisbergen K.P., Sanchez-Hernandez M., Geijtenbeek T.B., van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. Journal of Experimental Medicine 2005, 201:1281-1292.
120. Bennouna S., Bliss S.K., Curiel T.J., Denkers E.Y. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. Journal of Immunology 2003, 171:6052-6058.
121. Megiovanni A.M., Sanchez F., Robledo-Sarmiento M., Morel C., Gluckman J.C., Boudaly S. Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. Journal of Leukocyte Biology 2006, 79:977-988.
122. Huard B., McKee T., Bosshard C., Durual S., Matthes T., Myit S., et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. Journal of Clinical Investigation 2008, 118:2887-2895.
123. Costantini C., Cassatella M.A. The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity. Journal of Leukocyte Biology 2011, 89:221-233.
124. Jaeger B.N., Donadieu J., Cognet C., Bernat C., Ordoñez-Rueda D., Barlogis V., et al. Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. Journal of Experimental Medicine 2012, 209:565-580.